Department of Paediatrics, Division of Neonatology, Pediatric Intensive Care Medicine and Neuropaediatrics, Medical University of Vienna, Währingergürtel 18-20, 1090, Vienna, Austria.
Centre for Neonatal Research and Education, University of Western Australia, Perth, WA, Australia.
Eur J Pediatr. 2020 Aug;179(8):1325-1330. doi: 10.1007/s00431-020-03612-9. Epub 2020 Mar 16.
Pentoxifylline (PTX) is a candidate adjuvant medication for the treatment of sepsis and necrotizing enterocolitis in preterm infants. There is only limited data on safety and compatibility with other commonly used intravenous medications. This retrospective single-center study of 198 preterm infants (September 2012-September 2018) was performed at a level IV neonatal intensive care unit. Electronic data of all preterm infants who received pentoxifylline for sepsis or necrotizing were extracted from routine databases. We analyzed a total of 1081 PTX treatment days from 217 treatment episodes in 198 preterm infants (mean gestational age 27 weeks; mean birth weight 1060 g). At a mean daily dose of 28 mg/kg, no clinically relevant side effects were observed. PTX therapy was not associated with clinically significant changes of blood biochemistry and hematology parameters. Concomitant infusion of PTX with other common NICU medications was well tolerated, and there was no evidence of incompatibility.Conclusion: Intravenous PTX is compatible with standard NICU drugs and well tolerated in critically ill preterm infants. What is Know: •Currently, there are no evidence-based adjuvant medications available that target the harmful inflammatory host response in neonatal sepsis or necrotizing enterocolitis. •Pentoxifylline (PTX) is a candidate adjuvant medication for the treatment of sepsis and necrotizing enterocolitis in preterm infants; however, safety data are rare and PTX is currently used off-label. What is New: •Here we report on our experience in the pragmatic routine use of PTX as adjuvant therapy in 198 preterm infants with sepsis or NEC. •Concomitant infusion of PTX with other common NICU medications was well tolerated, and there was no evidence of incompatibility. No clinically relevant side effects were observed.
己酮可可碱（PTX）是一种候选辅助药物，可用于治疗早产儿败血症和坏死性小肠结肠炎。目前关于其安全性和与其他常用静脉内药物的兼容性的数据有限。这项回顾性单中心研究纳入了 198 例早产儿（2012 年 9 月至 2018 年 9 月），在 4 级新生儿重症监护病房进行。从常规数据库中提取了所有接受 PTX 治疗败血症或坏死性小肠结肠炎的早产儿的电子数据。我们分析了 198 例早产儿 217 例治疗事件中的 1081 个 PTX 治疗日（平均胎龄 27 周；平均出生体重 1060g）。在平均每天 28mg/kg 的剂量下，未观察到有临床意义的不良反应。PTX 治疗与血液生化和血液学参数的临床显著变化无关。PTX 与其他常见 NICU 药物同时输注可耐受良好，无不相容的证据。结论：在危重新生儿中，静脉内 PTX 与标准 NICU 药物相容且可耐受。已知：目前尚无针对新生儿败血症或坏死性小肠结肠炎中有害炎症宿主反应的循证辅助药物。己酮可可碱（PTX）是一种候选辅助药物，可用于治疗早产儿败血症和坏死性小肠结肠炎；然而，安全性数据很少，PTX 目前是在标签外使用。新发现：我们在此报告了我们在 198 例败血症或 NEC 早产儿中作为辅助治疗常规使用 PTX 的经验。PTX 与其他常见 NICU 药物同时输注可耐受良好，无不相容的证据。未观察到有临床意义的不良反应。
